Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Guessing the same, why buy 2 different preferred ?
Equal voting rights
I think some may want to read this a little slower to understand how it benefits them, if you own preferred shares
Uh, no
Read their Facebook message, delisting
Things a brewing
If like Zander , a private company to get commissions it won't affect anything
should be
Thanks for the hint, Koos
Always thought the veterinary route would profit first as there are less hoops to jump through and less competition.
PR s/b coming down the pike soon
News coming
10k out
Not true, reread prs
Science is slow, with positive testing it begins to move faster
The slow down effect is always on the way govt bureaucracy slows everything down.
End of Obama administration may mean a clearing house effect with gold stars for Obama bragging rights
C Ichim updated her LinkedIn site, saying she left last Dec
Everyone wants a Hail Mary score, but moving steady up field garners the same end result building on increased knowledge, data and testing. If you can't handle it move on, invest in gold mines and pot, Gita
I'm holding and building my
Portfolio
It's called working out contract details
It's not the company selling, but the company you keep here
SAN DIEGO, September 29, 2016 /PRNewswire/ --
Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) is pleased to announce that Xiaojing Ma, Ph.D. has agreed to serve in the consulting role as the Company's Senior Research Advisor. Specifically, he will be assisting Dr. Lander in pre-clinical research design and execution of cellular and animal experiments for the Company's NR2F6 program.
SAN DIEGO, September 29, 2016 /PRNewswire/ --
Regen BioPharma Inc. (OTCQB: RGBP), (OTCQB: RGBPP) is pleased to announce that Xiaojing Ma, Ph.D. has agreed to serve in the consulting role as the Company's Senior Research Advisor. Specifically, he will be assisting Dr. Lander in pre-clinical research design and execution of cellular and animal experiments for the Company's NR2F6 program.
New advisor has vet experience, moving on plan
read his resume
Tweet yesterday commending another company for getting FDA approval; seems they are watching FDA approvals closely lately......
Tweet yesterday commending another company for getting FDA approval; seems they are watching FDA approvals closely lately......
prepare
prepare
entering PR news cycle over next few weeks
entering PR news cycle over next few weeks
Uh wha?
FDA approval will be sooner than most think
Don't start caring too soon
Only 1 Ichim left
Ahhh finally Oct
Notice his resume, he started out with animal studies, should be able to help revive ENTB
This stock has the potential to be worth a thousandth of a cent in no time!
hold yer buys till EOD
One ancilary reason for the drop - for the last year, there is no mention of BMSN in RBGP PRs. They used to say at the beginning that RGBP was a subsidiary of BMSM, now they don't, so outside investors don't have a clue what BMSN is.
Wait till it does
I think f and f would be willing to wait for a higher, uplisted amount. Normal investors don't sell the ranch on incremental news, penny traders do